Literature DB >> 20713813

The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland.

Caitriona Ryan1, Benvon Moran, Malachi J McKenna, Barbara F Murray, Jennifer Brady, Paul Collins, Sarah Rogers, Brian Kirby.   

Abstract

OBJECTIVES: To determine whether narrowband UV-B (NB-UV-B) may mediate its beneficial effect on psoriasis by increasing vitamin D levels, and to assess the effect of NB-UV-B on vitamin D status in patients with psoriasis in wintertime.
DESIGN: A prospective controlled study from October 2008 to February 2009.
SETTING: A dermatology outpatient department at a university teaching hospital. PATIENTS: Thirty consecutive patients with psoriasis treated with NB-UV-B and 30 control patients with psoriasis were recruited. Control patients were recruited within 1 week of treated patients to control for seasonal variation of serum 25-hydroxyvitamin D [25(OH)D] levels. One patient with photo aggravated psoriasis was withdrawn from the study. INTERVENTION: Narrowband UV-B was administered 3 times per week. MAIN OUTCOME MEASURE: Serum 25(OH)D was measured at baseline, after 4 weeks and at completion of treatment.
RESULTS: Levels of serum 25(OH)D increased significantly(P< .001) from a median (range) of 23 (9-46)ng/mL at baseline to 51 [rather than 59, as given in the originally published article] (32-112) ng/mL at the end of NB–UV-B treatment compared with no change in the control group [corrected]. The change in serum 25(OH)D level correlated with the number of exposures of NB-UV-B (r = 0.61; P < .001) and cumulative UV-B dose (r = 0.47; P = .01) but not with treatment response. At the end of the study, all patients in the treatment group were vitamin D sufficient, but 75% of the control group had vitamin D insufficiency [serum 25(OH)D level <20 ng/mL]. In a multiple regression model, prior phototherapy was the sole predictor of baseline serum 25(OH)D level (r(2) = 0.13; P = .006), whereas the number of exposures of NB-UV-B predicted change in serum 25(OH)D level (r(2) = 0.38; P = .001).
CONCLUSIONS: Narrowband UV-B effectively increases serum 25(OH)D level while clearing psoriasis. Up to 75% of Irish patients with psoriasis were shown to be vitamin D insufficient during wintertime.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713813     DOI: 10.1001/archdermatol.2010.195

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.

Authors:  M J McKenna; B Murray; R Lonergan; J M T Redmond
Journal:  Ir J Med Sci       Date:  2012-04-07       Impact factor: 1.568

Review 2.  A dermatologist's perspective on vitamin D.

Authors:  Veena Vanchinathan; Henry W Lim
Journal:  Mayo Clin Proc       Date:  2012-03-14       Impact factor: 7.616

Review 3.  Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.

Authors:  Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas
Journal:  Nutrients       Date:  2021-04-29       Impact factor: 5.717

4.  Efficacy of narrowband ultraviolet B phototherapy and levels of serum vitamin D3 in psoriasis: A prospective study.

Authors:  Aditi Gupta; Trilok Chand Arora; Ankur Jindal; Ajeet Singh Bhadoria
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr

Review 5.  Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy.

Authors:  Anna A Brożyna; Radomir M Slominski; Bogusław Nedoszytko; Michal A Zmijewski; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

6.  Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance.

Authors:  Vybhav Jetty; Charles J Glueck; Ping Wang; Parth Shah; Marloe Prince; Kevin Lee; Michael Goldenberg; Ashwin Kumar
Journal:  N Am J Med Sci       Date:  2016-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.